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Abstract
Aim: Evidence of nutritional therapies in pancreatoduodenectomy (PD) has been 
shown. However, few studies focus on the association between different nutritional 
therapies and outcomes. The aim of this review was to summarize the current evi-
dence of nutritional therapies such as enteral nutrition (EN), immunonutrition, and 
synbiotics on postoperative outcomes after PD.
Methods: A systematic literature search of Embase, Medline Ovid, and Cochrane 
CENTRAL was done to summarize the available evidence, including randomized con-
trolled trials, meta‐analyses and reviews, regarding nutritional therapy in PD.
Results: A total of 20 randomized controlled trials were included in this review. Safety 
and tolerability of EN in PD was shown. Giving postoperative EN can shorten length 
of stay compared to parenteral nutrition; however, the effect of EN on postoperative 
complications remains controversial. Postoperative EN should be given only on se-
lective indications rather than routinely used, and preoperative EN is indicated only 
in patients with severe malnutrition. Giving preoperative immunonutrition is consid-
ered to reduce the incidence of infectious complications; however, evidence level is 
moderate and recommendation grade is weak. The beneficial effect of perioperative 
synbiotics on postoperative infectious complications is limited. Furthermore, the ef-
fectiveness of other nutritional supplements remains unclear.
Conclusion: Recently, evidence of enhanced recovery after surgery (ERAS) in PD has 
been increasing. Early oral intake with systematic nutritional support is an important 
aspect of the ERAS concept. Future well‐designed studies should investigate the im-
pact of systematic nutritional therapies on outcomes following PD.
K E Y W O R D S
enteral nutrition, immunonutrition, nutritional intervention, pancreatoduodenectomy, 
synbiotics
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1  | INTRODUC TION
Pancreatoduodenectomy (PD) is a highly invasive procedure in ab-
dominal surgery. Outcomes following PD have improved due to the 
development of the operative technique, surgical instruments, and 
perioperative management; however, complication and mortality 
rates are still high.1‒3 To improve clinical outcomes in gastrointes-
tinal surgery, perioperative nutritional therapy is considered to be 
important.
A previous review regarding perioperative nutritional support 
in patients undergoing PD was published in 2006 and suggested 
that enteral nutrition (EN) is associated with lower incidence of 
postoperative infections.4 However, this review evaluated only 
four studies focused on patients who underwent PD, including 
two randomized controlled trials (RCT), and further studies on this 
issue have been reported since 2006. Furthermore, the concept 
of enhanced recovery after surgery (ERAS), a multimodal strategy 
aimed to accelerate postoperative recovery, has recently been 
rapidly spreading in the field of PD.5,6
The aim of the present review was to overview the current ev-
idence of nutritional therapies such as EN, immunonutrition (IM), 
synbiotics and other nutritional supplements as a nutritional aspect 
of the ERAS concept, and to evaluate the association between nutri-
tional therapies and postoperative outcomes in patients undergoing 
PD.
2  | MATERIAL S AND METHODS
A systematic literature search of Embase, Medline Ovid, and 
Cochrane CENTRAL was carried out on January 11, 2019 using 
the following key words: diet therapy, enteral nutrition, synbiotics, 
supplements, enhanced recovery after surgery, and pancreatoduo-
denectomy (Table S1). The search was limited to RCT, meta‐analyses, 
and reviews in English. The present study included articles report-
ing outcomes of nutritional therapies in patients following PD. After 
removing duplicate records, abstracts were screened independently 
by two investigators to determine eligible studies for further analy-
sis. Full‐text articles of the remaining records were subsequently 
retrieved and screened independently by two investigators. The pre-
sent study is reported according to the Preferred Reporting Items 
for Systematic Reviewers and Meta‐Analyses (PRISMA) guidelines.7
3  | RESULTS
A systematic search of the literature identified 590 articles, 20 RCT 
which matched the inclusion criteria: EN (n = 6); IM (n = 7); synbiot-
ics (n = 2); other nutritional supplements (n = 3); and ERAS (n = 2) 
(Figure 1). Summary of all the included studies is represented in 
Table 1, showing sample size, type of intervention, timing of inter-
vention, and outcomes.
F I G U R E  1   PRISMA 2009 flow diagram 
of articles included in the present review
622  |     TAKAGI eT Al.
TA B L E  1   Summary of randomized controlled trials included in the present review
Study Year
Study 
design Sample size
Intervention 
(Timing) Outcomes Conclusions
Enteral nutrition
Mack 
et al8
2004 Single 
center
20 vs 16 EN (Post) vs 
SC (Post)
Major complications: 5 vs 
25% (P = .15)
Gastric decompression and 
EN through a double‐lumen 
gastrojejunostomy tube 
improved outcomes
DGE: 0 vs 25% (P = .03)
LOS: 11.5 vs 15.8 d (P = .01)
Grizas 
et al9
2008 Single 
center
30 vs 30 EN (Post) vs 
SC (Post)
Complications: 23.3 vs 
53.3% (P = .03)
EN helped to decrease the 
incidence of infectious 
complicationsInfectious complications: 
16.7 vs 46.7% (P = .025)
Mortality: 0 vs 6.7% (P = .49)
Tien et al10 2009 Single 
center
123 vs 124 EN (Post) vs 
TPN (Post)
Major complications: 9.8 vs 
9.7% (P = .98)
EN and biliopancreatic diver-
sion minimized impacts of 
DGEInfectious complications: 
21.1 vs 23.6% (P = .67)
DGE: 16.3 vs 21.7% (P = .27)
POPF: 4.9 vs 5.6% (P = .79)
Mortality: 1.6 vs 1.6% 
(P = .99)
Liu et al11 2011 Single 
center
30 vs 30 EN (Post) vs 
TPN (Post)
DGE: 0 vs 20% (P = .039) EN was superior to TPN
POPF: 3.6 vs 26.7% 
(P = .039)
LOS: 17.8 vs 19.2 d (P = .375)
Mortality: 0 vs 0%
Park 
et al12
2012 Single 
center
20 vs 20 EN (Post) vs 
TPN (Post)
DGE: 11 vs 5% (P = .485) EN was associated with pres-
ervation of weight compared 
with TPN and with recovery 
of digestive function after PD
POPF: 11 vs 5% (P = .485)
LOS: 23.2 vs 25.3 d 
(P = .991)
Perinel 
et al13
2016 Multicenter 103 vs 101 EN (Post) vs 
TPN (Post)
Complications: 77.5 vs 
64.4% (P = .04)
EN is not recommended in 
terms of safety and feasibility
Infectious complications: 
39.2 vs 41.6% (P = .71)
DGE: 34.3 vs 27.3% 
(P = .281)
POPF: 48.1 vs 27.7% 
(P = .012)
LOS: 25.8 vs 23.6 d 
(P = .181)
90‐day mortality: 9.7 vs 3% 
(P = .049)
Immunonutrition
Di Carlo 
et al14
1999 Single 
center
33 vs 35 vs 32 IM (Post) vs 
EN (Post) vs 
TPN (Post)
Complications: 33.5 vs 40.0 
vs 59.5% (P = .05)
IM seemed to improve 
outcome
Infectious complications: 9.1 
vs 17.2 vs 25.0%
DGE: 9.1 vs 5.7 vs 12.5%
POPF: 9.1 vs 11.4 vs 12.4%
LOS: 16.3 vs 17.8 vs 19.3 d 
(P < .05)
Mortality: 3.3 vs 0 vs 6.2%
(Continues)
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Study Year
Study 
design Sample size
Intervention 
(Timing) Outcomes Conclusions
Gianotti 
et al15
2000 Single 
center
71 vs 73 vs 68 EN/IM (Post) 
vs EN (Post) 
vs TPN (Post)
Complications: 33.8 vs 43.8 
vs 58.8% (P = .005)
IM ameliorated the immu-
nometabolic response and 
improves outcome compared 
to parenteral feeding
Infectious complications: 8.4 
vs 15.1 vs 22.1% (P = .04)
DGE: 11.3 vs 12.3 vs 14.7%
POPF: 9.9 vs 12.3 vs 11.8%
LOS: 15.1 vs 17.0 vs 18.8 d 
(P < .05)
Mortality: 2.8 vs 1.4 vs 5.8%
Hamza 
et al16
2015 Single 
center
17 vs 20 IM (Peri) vs SC 
(Post)
Patients with IM had 
significantly higher total 
lymphocyte count on POD 
3 and significantly greater 
rise in CD4/CD8 ratio from 
POD 3 to POD 7
Perioperative IM was associ-
ated with favorable modula-
tion of the inflammatory 
response and enhancement of 
systemic immunity
Suzuki 
et al17
2010 Single 
center
10 vs 10 vs 10 IM (Peri) vs IM 
(Post) vs TPN 
(Post)
Infectious complications: 10 
vs 60 vs 60% (P < .05)
Perioperative IM re-
duced stress‐induced 
immunosuppression
Aida 
et al18
2014 Single 
center
25 vs 25 IM (Pre)/EN 
(Post) vs EN 
(Post)
Infectious complications: 28 
vs 60% (P = .023)
Preoperative IM may stop ag-
gravation of complications
DGE: 20 vs 12% (P = .44)
POPF: 20 vs 28% (P = .51)
Miyauchi 
et al19
2019 Single 
center
30 vs 30 IM (Peri) vs IM 
(Pre)
Infectious complications: 
13.3 vs 26.7% (P = .166)
No additional effects of perio-
perative IM on postoperative 
immunity and infectious 
complications compared with 
preoperative IM
DGE: 6.7 vs 13.3% (P = .389)
POPF: 20 vs 33.3% 
(P = .371)
Mortality: 0 vs 0%
Ashida 
et al20
2018 Single 
center 
double‐
blinded
11 vs 9 IM (Pre) vs no‐
IM (Pre)
Complications: 91 vs 78% 
(P = .57)
Preoperative IM had no 
marked impact on rates 
of postoperative hyper-
cytokinemia or infectious 
complications
Infectious complications: 55 
vs 78% (P = .37)
POPF: 54.5 vs 44.4% 
(P = .99)
Mortality: 0 vs 0%
Synbiotics
Rayes 
et al21
2007 Single 
center 
double‐
blinded
40 vs 40 SN (Peri) vs 
no‐SN (Peri)
Infectious complications: 
12.5 vs 40% (P = .005)
SN reduced bacterial infection 
rates and antibiotic therapy
DGE: 2.5 vs 10% (ns)
POPF: 7.5 vs 10% (ns)
LOS: 17 vs 22 d (ns)
Mortality: 2.5 vs 2.5% (ns)
Yokoyama 
et al22
2016 Single 
center
22 vs 22 SN (Pre) vs no‐
SN (Pre)
Major complications: 45 vs 
27% (P = .21)
Preoperative SN did not affect 
the incidence of infectious 
complicationsInfectious complications: 41 
vs 36% (P = .757)
DGE: 9 vs 27% (P = .12)
POPF: 36 vs 14% (P = .08)
LOS: 37 vs 35 d (P = .68)
Mortality: 5 vs 0%
TA B L E  1   (Continued)
(Continues)
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3.1 | Enteral nutrition
Recent guidelines of the American Society for Parenteral and Enteral 
Nutrition for EN therapy recommended postoperative EN when fea-
sible within 24 hours after surgery.28 Guidelines of the European 
Society for Parenteral and Enteral Nutrition for clinical nutrition in 
surgery recommended postoperative EN within 24 hours in patients 
in whom early oral nutrition cannot be started, and in whom oral 
intake will be inadequate for more than 7 days.29 However, we need 
to pay attention to the risks of PD‐related complications such as 
postoperative pancreatic fistula (POPF) and delayed gastric empty-
ing (DGE).
In a RCT (Mack et al8) evaluating the effects of inserting a dou-
ble‐lumen gastrojejunostomy tube after PD, patients were ran-
domized to EN given by gastrojejunostomy tube (n = 20) or to the 
routine care group (n = 16). Authors reported the benefit of gastric 
decompression and EN through the gastrojejunostomy tube in terms 
of reducing DGE (0% vs 25%, P = .03) and postoperative length of 
Study Year
Study 
design Sample size
Intervention 
(Timing) Outcomes Conclusions
Other nutritional supplementation
Jo et al23 2006 Single 
center 
double‐
blinded
32 vs 28 Glu (Peri) vs 
no‐Glu (Peri)
Complications: 37.5 vs 
28.6% (P = .46)
No beneficial effect of 
Glu supplementation on 
outcomesDGE: 12.5 vs 14.3% (ns)
POPF: 6.3 vs 0% (ns)
LOS: 14.0 vs 14.5 d (P = .20)
Mortality: 3.1 vs 0% (P = .35)
Braga 
et al24
2012 Single 
center 
double‐
blinded
18 vs 18 pONS (Peri) 
vs no‐pONS 
(Peri)
Plasma levels of vitamin 
C (P = .001), selenium 
(P = .07), and zinc (P = .06) 
were higher in the pONS 
group on POD 1
Perioperative pONS positively 
affected plasma vitamin C 
levels and improved total 
endogenous antioxidant 
capacity, but did not reduce 
oxidative stress and systemic 
inflammation markers
No difference was found 
in C‐reactive protein levels 
after surgery in either 
group
Zhu et al25 2013 Single 
center
38 vs 38 PUFA (Post) 
vs no‐PUFA 
(Post)
Infectious complications: 
36.8 vs 57.9% (P < .05)
PUFA can improve nutritional 
status, decrease the incidence 
of infectious complications, 
and shorten LOS
DGE: 7.9 vs 5.3% (ns)
POPF: 2.6 vs 2.6% (ns)
LOS: 13.5 vs 15.3 d (P < .05)
Mortality: 0 vs 0%
Enhanced recovery after surgery
Takagi 
et al26
2018 Single 
center
37 vs 37 ERAS (Peri) vs 
SC (Peri)
Complications: 32.4 vs 
56.8% (P = .034)
ERAS contributed to earlier 
recovery and shorter hospital 
stay without compromising 
surgical outcomes
Infectious complications: 19 
vs 41% (P = .04)
DGE: 10.8 vs 8.1% (P = .34)
POPF: 18.9 vs 27.0% 
(P = .12)
LOS: 20.1 vs 26.9 d 
(P < .001)
Mortality: 0 vs 0%
Deng 
et al27
2017 Single 
center
76 vs 83 ERAS (Peri) vs 
SC (Peri)
DGE: 20 vs 39% (P = .02) ERAS protocol significantly re-
lieved physiological stress and 
accelerated recovery thereby 
reducing LOS
POPF: 51 vs 43% (P = .52)
LOS: 15 vs 19 d (P = .024)
Mortality: 0 vs 0%
Abbreviations: DGE, delayed gastric emptying; EN, enteral nutrition; ERAS, enhanced recovery after surgery; Glu, glutamine; IM, immunonutrition; 
LOS, length of stay; ns, not significant; PD, pancreatoduodenectomy; pONS, preconditioning oral nutritional supplement; POPF, postoperative pan-
creatic fistula; PUFA, polyunsaturated fatty acids; SC, standard care; SN, synbiotics; TPN, total parenteral nutrition.
TA B L E  1   (Continued)
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stay (LOS) (11.5 days vs 15.8 days, P = .01). However, this study fo-
cused on the effects of the gastrojejunostomy tube rather than on 
EN; therefore, it is difficult to interpret whether the results were due 
to the tube or to the effects of EN.
Another RCT (Grizas et al9) comparing EN (n = 30) with standard 
oral diet (n = 30) after PD found a reduction in postoperative infec-
tions in postoperative EN of 16.7% vs 46.7% (P = .025). Regarding 
DGE, no significant difference was shown between the groups (10% 
vs 3.3%, P = .61). Effect of EN on LOS was unclear.
Effects of EN and biliopancreatic diversion with modified Roux‐
en‐Y gastrojejunostomy reconstruction after PD were investigated in 
a RCT (Tien et al10). Two hundred and forty‐seven patients were ran-
domized to the EN group with modified Roux‐en‐Y gastrojejunostomy 
reconstruction (n = 123) or to the control group with total parenteral 
nutrition (TPN) support. Results showed no significant differences 
between the two groups in terms of LOS, and postoperative compli-
cations including DGE (16.3% vs 21.7%, P = .27), POPF (4.9% vs 5.6%, 
P = .79), infections (21.1% vs 23.6%, P = .67), and mortality (1.6% vs 
1.6%, P = .99). However, it remains difficult to determine whether the 
results are secondary to EN or to the modified reconstruction.
Effects of EN and TPN were examined by three RCT in patients 
undergoing PD and different outcomes were shown.11‒13 In a RCT 
(Liu et al11), 60 patients were randomly divided into the EN group 
(n = 30) and the TPN group (n = 30). EN was not associated with LOS 
(17.8 days vs 19.2 days, P = .375). However, EN was associated with 
lower incidences of DGE (0% vs 20%, P = .039) and POPF (3.6% vs 
26.7%, P = .039). Another RCT (Park et al12) comparing the EN group 
(n = 20) with the TPN group (n = 20) showed that EN was not asso-
ciated with LOS (23.2 days vs 25.3 days, P = .991) and postoperative 
complications including DGE (11% vs 5%, P = .485) and POPF (11% 
vs 5%, P = .485). However, EN was associated with preservation of 
body weight and recovery of digestive function after PD.12 A recent 
multicenter RCT (Perinel et al13) involving nine centers in France ran-
domized 204 patients to EN (n = 103) or TPN (n = 101) groups. The 
EN group had a significantly higher incidence of overall postopera-
tive complications than the TPN group (77.5% vs 64.4%, P = .04). In 
addition, EN was associated with a higher incidence of POPF (48.1% 
vs 27.7%, P = .012). There were no significant differences in the in-
cidence of DGE (34.3% vs 27.3%, P = .281), infectious complications 
(39.2% vs 41.6%, P = .71), and LOS (25.8 days vs 23.6 days, P = .181). 
It was concluded that EN should not be recommended in terms of 
safety and feasibility.
A meta‐analysis of four RCT8‒10,15 was conducted in 2013 to 
evaluate the safety and effectiveness of early enteral nutrition for 
patients with PD, including 246 patients with early EN and 238 
patients with other nutritional therapies.30 Results showed no sig-
nificant differences in DGE (OR: 0.89, 95% CI: 0.36‐2.18, P = .79), 
intra‐abdominal complications (OR: 0.82, 95% CI: 0.53‐1.26, P = .37), 
mortality (OR: 0.43, 95% CI: 0.11‐1.62, P = .21), infection (OR: 0.55, 
95% CI: 0.29‐1.07, P = .08), and LOS (mean difference −0.93, 95% 
CI: −6.51‐4.65, P = .74). The authors concluded that early EN is safe 
and tolerable in patients undergoing PD. A recent literature review 
regarding EN in PD has also shown that EN is safe and well tolerated, 
but does not have clear advantages reducing DGE, POPF, postoper-
ative hemorrhage, infectious complications and LOS.31 In contrast, 
the latest meta‐analyses comparing EN to TPN in patients after PD 
have shown that EN is associated with a significantly shorter LOS. 
However, EN had no effect on reducing postoperative complications 
including POPF, DGE, and infectious complications.32,33
Guidelines for perioperative care of PD by the ERAS Society 
have recommended starting a normal diet without restriction after 
surgery, giving EN only for specific patients, and not routinely giving 
TPN.5,6 Furthermore, the International Study Group on Pancreatic 
Surgery (ISGPS) has provided evidence on nutritional support in 
pancreatic surgery, encouraging early oral intake within ERAS proto-
cols.34 However, they have recommended considering postoperative 
EN in patients who were preoperatively malnourished, those at high 
risk of developing malnutrition, and those who develop severe post-
operative complications including those undergoing reoperation.
Regarding the timing of intervention, the effect of postoperative 
EN in PD has been investigated in all RCT.8‒13 Definitive advantages 
of preoperative EN remain unclear in patients with PD. However, 
even though the evidence level is low, according to the ERAS guide-
lines and the ISGPS consensus, preoperative nutritional support 
with EN, TPN, and supplements can be optimized only in severe mal-
nourished patients.5,6,34
In summary, the safety and tolerability of EN in PD has been 
shown according to several meta‐analyses and a review.30‒33 Giving 
postoperative EN can shorten LOS compared to TPN; however, 
the effect of EN on postoperative complications following PD re-
mains controversial. The concept of selective indication for artifi-
cial nutrition rather than routine use should be discussed.5,6,15,34 
Furthermore, preoperative EN should be indicated only in patients 
with severe malnutrition.5,6,34
3.2 | Immunonutrition
Effect of IM has been examined over many years, and several sys-
tematic reviews have shown beneficial outcomes of IM in patients 
following gastrointestinal surgery.35‒37
The earliest RCT (Di Carlo et al14) to address the problem of 
IM in patients undergoing PD was reported in 1999, comparing 
IM with standard enteral formula (n = 33), standard enteral for-
mula (n = 35), and TPN (n = 32). IM included arginine, omega‐3 
fatty acid and RNA, and postoperative feeding was given within 
12 hours after surgery. Incidence of postoperative complications 
was lower in the IM group (33.5%) than in the standard group 
(40.0%) and the TPN group (59.5%, P = .05). In addition, the sever-
ity of infectious complications (sepsis score) was lower in the IM 
group than in the standard group and the TPN group (5.5 vs 7.9 
vs 10.4%, P < .05), and LOS was shorter in the IM group than in 
the standard group and the TPN group (16.3 days vs 17.8 days vs 
19.3 days, P < .05).
Another RCT (Gianotti et al15) comparing EN with IM group 
(n = 71), the EN group (n = 73), and the TPN group (n = 68) showed 
a lower incidence of postoperative complications in the EN with IM 
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group than in the EN group and the TPN group (33.8% vs 43.8% 
vs 58.8%, P = .005), and shorter LOS in the IM group (15.1 days vs 
17.0 days vs 18.8 days, P < .05).
In a RCT (Hamza et al16) investigating the effects of perioperative 
IM (n = 17) versus standard enteral nutrition (n = 20) on system-
atic and mucosal immunity in patients with PD, results showed that 
giving perioperative IM is associated with a favorable modulation of 
the inflammatory response and enhancement of systemic immunity. 
However, the effect of perioperative IM on outcomes following PD 
remains unclear.
The Chiba group in Japan carried out three RCT to investigate 
the effects of IM in patients with PD focusing on the timing of 
giving IM.17‒19 The first RCT (Suzuki et al17) compared periopera-
tive IM therapy (n = 10), postoperative IM therapy (n = 10), and 
TPN therapy (n = 10) and showed that perioperative IM reduced 
stress‐induced immunosuppression and the incidence of infectious 
complications (10% vs 60% vs 60%, P < .05). The second RCT (Aida 
et al18) compared preoperative IM therapy (n = 25) with no preoper-
ative IM therapy (n = 25) and concluded that preoperative IM could 
help to establish a favorable immunonutrient profile before surgery 
and to protect against the aggravation of postoperative complica-
tions. The third RCT (Miyauchi et al19) evaluated the additional ef-
fect of perioperative IM (n = 30) compared with preoperative IM 
(n = 30) and showed no additional effects of perioperative IM on 
postoperative immunity and infectious complications compared 
with preoperative IM (13.3% vs 26.7%, P = .166). Accordingly, giving 
preoperative IM was suggested to prevent infectious complications 
following PD. However, the effect of IM on LOS was not investi-
gated in these trials.
The first double‐blinded RCT (Ashida et al20) was conducted to 
compare outcomes between the control group (standard nutrition, 
n = 9) and the treatment group (preoperative eicosapentaenoic 
acid‐enriched nutrition, n = 11) after PD. There were no significant 
differences in perioperative interleukin‐6 levels between the two 
groups (P = .68). Furthermore, no significant differences were found 
in the incidence of infectious complications (55% vs 78%, P = .37) 
and overall complications (91% vs 78%, P = .57). No data on LOS 
were reported.
Giving preoperative IM is considered to reduce the incidence of 
infectious complications after PD; however, the evidence level of 
IM is moderate and the recommendation grade is weak according to 
the guidelines for perioperative care for PD by the ERAS Society.5,6 
Further well‐designed studies with a large number of patients are 
required to address the current evidence.
3.3 | Synbiotics
Synbiotics consists of probiotics and prebiotics. Probiotics, live ben-
eficial bacteria, can influence pathogenic mechanisms of bacterial 
translocation by increasing intestinal motility, stabilizing the intes-
tinal barrier, and enhancing the innate immune system.21 Prebiotics, 
such as fiber, is a non‐digestible dietary ingredient that serves as a 
nutritional source for probiotics. Giving synbiotics may be helpful in 
preventing bacterial translocation especially following highly inva-
sive surgery.
A first double‐blind RCT (Rayes et al21) was conducted in pa-
tients following PD, in which 40 patients received a composition of 
Lactobacillus and fiber and 40 patients received placebo (fiber only) 
starting the day before surgery and continuing for 8 days. The syn-
biotics group had a significantly lower incidence of postoperative 
infections than the placebo group (12.5% vs 40%, P = .005), and a 
shorter duration of antibiotic therapy (2 ± 5 days vs 10 ± 14 days, 
P = .015). However, no significant differences were found in LOS 
(17 days vs 22 days), other complications (23% vs 25%), and mortal-
ity (2.5% vs 2.5%).
Another RCT (Yokoyama et al,22) compared preoperative synbi-
otics (n = 22) with no synbiotics (n = 22) and showed no significant 
differences with respect to the incidence of infectious complica-
tions following PD (41% vs 36%, P = .76), POPF (≥grade B) (36% vs 
14%, P = .08), DGE (≥grade B) (9% vs 27%, P = .12), and median LOS 
(37 days vs 35 days, P = .68).
Beneficial outcomes have been shown in a recent systematic 
review of 11 RCT in patients following highly invasive abdominal 
surgery.38 It was concluded that improving the intestinal microen-
vironment and intestinal barrier function before surgery is crucial to 
prevent postoperative infections following highly invasive surgery. 
Use of preoperative synbiotics could be helpful to improve intestinal 
microflora, and prevent bacterial translocation and the incidence of 
infectious complications.
Another systematic review of 28 RCT including 2511 patients 
following gastrointestinal surgery showed that giving perioperative 
synbiotics may prevent postoperative infections; however, the re-
sults need to be interpreted with caution as a result of the risk of bias 
and the potential publication bias.39
Although recent reviews has shown the effectiveness of synbi-
otics in preventing postoperative infections in gastrointestinal sur-
gery,38,39 different outcomes were shown in two RCT after PD.21,22 
Sample sizes of these trials were small, and postoperative infectious 
complications after PD were mainly associated with the incidence of 
POPF. Therefore, the effect of synbiotics may be limited especially 
in patients following PD.
3.4 | Other nutritional supplements
To assess the effect of glutamine supplementation in patients un-
dergoing PD, a double‐blinded RCT (Jo et al23) was conducted and 
the results were reported in 2006. From the second preoperative 
day to the fifth postoperative day, isonitrogenous amino acid with 
glutamine (0.2 g/kg per day) was given to 32 patients (the glutamine 
group), while another 28 patients received isonitrogenous amino 
acid (control group). Median LOS and postoperative nutritional sta-
tus were not different between the two groups. In addition, no sig-
nificant differences were found in overall complications (glutamine 
group 37.5% vs control group 28.6%, P = .46) and PD‐related com-
plications (25.0% vs 14.3%, P = .30). This study showed no beneficial 
effect of glutamine supplementation in patients with PD.
     |  627TAKAGI eT Al.
Another double‐blinded RCT (Braga et al24) was carried out to 
evaluate the impact of a carbohydrate‐containing preconditioning 
oral nutritional supplement (pONS) enriched with glutamine, anti-
oxidants, and green tea extract on postoperative oxidative stress. 
Patients were randomized to receive either pONS (n = 18) or placebo 
(n = 18) twice the day before surgery and once 3 hours before sur-
gery. Giving perioperative pONS positively affected plasma vitamin 
C levels and improved total endogenous antioxidant capacity shortly 
after PD, but did not reduce oxidative stress and systemic inflamma-
tion markers.
Effect of parenteral fish oil lipid emulsion in TPN combined with 
EN support was evaluated in a RCT (Zhu et al25), including a polyun-
saturated fatty acid (PUFA) group with parenteral fish oil lipid emul-
sion in PN combined with EN support for 5 days after PD (n = 38) and 
a control group (n = 38). Incidence of infectious complications in the 
PUFA group was significantly decreased (36.8% vs 57.9%, P < .05), as 
well as mean LOS (13.5 ± 3.8 days vs 15.3 ± 4.3 days, P < .05).
No significant beneficial effects of glutamine supplementation 
and pONS were shown in double‐blinded RCT.23,24 In contrast, the 
beneficial effect of PUFA was shown in a RCT.25 However, this trial 
was not double‐blinded and the number of included patients was 
small. Therefore, further studies, including a large multicenter trial, 
are warranted for determining the effects of these nutritional sup-
plements in patients undergoing PD.
3.5 | Enhanced recovery after surgery
Guidelines for perioperative care for PD have been published in 
2012 by the ERAS Society in which available evidence was summa-
rized and recommended for 27 care items.5,6 However, the evidence 
of ERAS pathways for PD is limited because no RCT has been con-
ducted to examine the effect of ERAS protocols in patients with PD.
In 2013, Coolsen et al40 published a systematic review and 
meta‐analysis regarding ERAS in patients with pancreatic surgery. 
The authors examined eight studies, including five case‐control 
studies, two retrospective studies, and one prospective study, and 
meta‐analysis of four studies focusing on PD showed a significant 
difference in complication rates in favor of the ERAS group (absolute 
risk difference 8.2%, 95% CI: 2.0‐14.4, P = .008). They implied that 
ERAS protocols in pancreatic surgery helped to shorten LOS without 
compromising morbidity and mortality.
A further systematic review and meta‐analysis was published 
in 201641 investigating the effects of implementing ERAS proto-
cols following PD. In this study, 14 case‐control studies with 1409 
ERAS patients and 1310 control patients were analyzed. Meta‐anal-
ysis showed that patients in the ERAS group had shorter LOS com-
pared with those in the control group (weighted mean differences 
−4.17 days, 95% CI: −5.72 to −2.61, P < .001). In addition, implemen-
tation of ERAS protocols reduced DGE (OR: 0.56, 95% CI: 0.44‐0.71, 
P < .001), overall morbidity (OR: 0.63, 95% CI: 0.54‐0.74, P < .001), 
and in‐hospital costs compared to the control group. There were no 
statistically significant differences in other postoperative outcomes 
such as POPF, mortality and readmission rate.
A review by Pecorelli et al,42 including 17 non‐randomized stud-
ies, showed that ERAS protocols for pancreatic surgery are safe 
with no difference in postoperative morbidity, leading to early dis-
charge and no increase in hospital readmissions. Furthermore, hos-
pital costs were reduced as a result of better organization of care 
and resource use. In this study, authors summarized the specific 
elements as ERAS protocols, and nutritional therapy including im-
munonutrition and early oral nutrition was suggested as one of the 
key elements in ERAS. However, the authors stated that the role of 
ERAS pathways for pancreatic surgery is still unclear as high‐quality 
RCT are lacking.
Takagi et al26 carried out a RCT to examine the efficiency of 
ERAS protocols in patients following PD. Mean LOS in the ERAS 
group was significantly shorter than that in the control group 
(20.1 ± 5.4 days vs 26.9 ± 13.5 days, P < .001). The ERAS group had 
a significantly lower percentage of postoperative complications 
(32.4% vs 56.8%, P = .034) and infectious complications (19% vs 
41%, P = .04). No significant differences between the groups were 
found in terms of POPF (≥grade B) (18.9% vs 27.0%, P = .12) and 
DGE (≥grade B) (10.8% vs 8.1%, P = .34). As this study included 
nutritional therapy such as immunonutrition, synbiotics, and EN in 
the ERAS protocols, nutritional therapy could contribute to earlier 
gastrointestinal function and accelerate postoperative recovery 
after PD.
In another RCT, Deng et al27 investigated the feasibility and 
safety of implementing the modified ERAS protocols based on co-
lonic surgery in patients undergoing PD. A total of 159 patients 
were randomized into two groups: either ERAS (n = 76) or con-
ventional protocol (n = 83). Authors reported that the ERAS group 
patients had shorter LOS (15 ± 8 vs 19 ± 10 days, P = .024) with 
comparable postoperative complications as follows: DGE (20% 
vs 39%, P = .02); POPF (51% vs 43%, P = .52); re‐laparotomy (4% 
vs 1%, P = .60); and mortality (0% vs 0%). Several postoperative 
recovery factors were greatly improved in the ERAS group, and 
there were no complications requiring readmission. However, nu-
tritional therapy was not included as one element of the ERAS pro-
tocols in this study.
Accordingly, the evidence of ERAS in PD has been shown by recent 
meta‐analyses and RCT.26,27,40‒42 Systematic nutritional support is an 
important element of the ERAS concept; however, not all studies have 
investigated the effect of nutritional therapy within ERAS pathways. 
In addition, which nutritional therapy should be used as perioperative 
systematic nutritional support in patients following PD? Future well‐
designed studies should introduce nutritional therapies within ERAS 
protocols and investigate the impact of them on outcomes after PD.
4  | CONCLUSIONS
The present review summarized the available evidence regarding nu-
tritional therapy in patients following PD. Regarding the administration 
of EN, safety and tolerability of EN in PD has been shown. Giving post-
operative EN compared to TPN can shorten length of hospital stay; 
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however, the effect of EN on postoperative complications following 
PD remains controversial. Postoperative EN should be given only on 
selected indications rather than routinely used, and preoperative EN 
should be given only in patients with severe malnutrition. Giving pre-
operative IM should be considered in order to reduce the incidence 
of infectious complications after PD; however, evidence level of IM is 
moderate and recommendation grade is weak. The beneficial effect 
of perioperative synbiotics on postoperative infectious complications 
is limited in patients following PD. Furthermore, the effectiveness of 
other nutritional supplementation remains unclear. Recently, evidence 
for ERAS in PD has been increasing. Early oral intake should be allowed 
without restriction. In addition, systematic nutritional support should 
be an important aspect of the ERAS concept. Future well‐designed 
studies should investigate the impact of systematic nutritional thera-
pies on outcomes following PD.
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